On June 20, 2013, Heckel, Armin; Blum, Andreas; Hamprecht, Dieter; Kley, Joerg published a patent.Recommanded Product: Methyl 2-(3-formylphenyl)acetate The title of the patent was Preparation of heterocyclic compounds for treating lung and airways diseases. And the patent contained the following:
The present invention relates to compounds I [R1, R2 = H or alkyl; R3, R4 = H or Me; or R3 and R4 together form ethylene bridge; R5 = H, alkyl, alkylOC(O), etc.; R6 = H, halo, CN, etc.; R7 = H, halo, CN, etc.; R8 = H, halo, CN, etc.; R9 = H or Me; m, n = 0-2 (with the proviso that m+n<4); X = halo; L1 = a bond, CH2, CH2CH2, CH2O, etc.] and the tautomers and the salts thereof, particularly the pharmaceutically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacol. properties, particularly an inhibitory effect on epithelial sodium channels, the use thereof for the treatment of diseases, particularly diseases of the lungs and airways. Over 100 compounds I were prepared For example, reacting 3,5-diamino-6-chloro-N-[(methylsulfanyl)methanimidoyl]pyrazine-2-carboxamide with Me (4-aminopiperidin-1-yl)methyl-3-methoxybenzoate afforded 44% II. Exemplified compounds I were tested for their epithelial sodium channel inhibitory activity (data given). Pharmaceutical compositions comprising compound I, alone or in combination with other therapeutic agents, were disclosed. The experimental process involved the reaction of Methyl 2-(3-formylphenyl)acetate(cas: 142327-44-4).Recommanded Product: Methyl 2-(3-formylphenyl)acetate
The Article related to heterocyclic pyrazinecarboxamide preparation epithelial sodium channel enac inhibitor allergy, lung airway respiratory disease treatment antiasthmatic heterocyclic pyrazinecarboxamide preparation and other aspects.Recommanded Product: Methyl 2-(3-formylphenyl)acetate
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics